Dexcom’s Q2 Earnings Exceed Wall Street Expectations; Holds G7 Launch
Executive Summary
Dexcom expects 2020 revenues to reach $1.85bn driven by new patient adoption of its CGM device, but will not launch its next-gen G7 this year.
You may also be interested in...
Dexcom Outlines Three-Pronged Growth Strategy To Reach $4-4.5BN Revenue Goal By 2025
Dexcom’s growth strategy includes growing its core business, expanding into pharmacy sales channel, and expanding into new markets.
Beyond Diabetes: Abbott Launches Glucose Sport Biosensor For Athletes To Track Blood Sugar
Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.
Abbott Sees Signs Of Post-Pandemic Recovery In Q2
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
This content is free with registration!
Start a free trial today!
Register to keep reading and receive our free email digests